Get the Stockscreener App
0.2979
2.72%
0.0079
Pre-market:
.29
-0.0079
-2.65%
Azitra Inc stock is traded at $0.2979, with a volume of 171.68K.
It is up +2.72% in the last 24 hours and down -16.55% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.29
Open:
$0.2716
24h Volume:
171.68K
Relative Volume:
0.03
Market Cap:
$4.46M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0133
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-5.76%
1M Performance:
-16.55%
6M Performance:
-41.59%
1Y Performance:
+37.66%
1-Day Range:
$0.2716
$0.308
1-Week Range:
$0.2716
$0.3333
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2979 | 4.46M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Azitra Inc Stock (AZTR) Latest News
Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Acquired by Virtu Financial LLC - Defense World
Azitra (AZTR) Expected to Announce Quarterly Earnings on Friday - Defense World
Azitra to Present at Microbiome Times Partnering Forum – Company Announcement - Financial Times
Precision Dermatology Leader Azitra Reveals Growth Strategy at Major Microbiome Forum - Stock Titan
AZTR: Netherton Topline Expected by Year-End - MSN
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 144.1% in February - Defense World
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates - Citizentribune
Azitra, Inc. Announces FY 2024 Financial Results and Business Updates - Defense World
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating - Investing.com
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating By Investing.com - Investing.com South Africa
Can Azitra's $1B Market Opportunity Offset Its Revenue Decline? Key 2024 Metrics Revealed - Stock Titan
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle - HPBL
Monitoring Azitra Inc (AZTR) after recent insider movements - Knox Daily
AZTR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Azitra Inc (AZTR) looking to reclaim success with recent performance - SETE News
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Cap:
|
Volume (24h):